Skip to main content

Table 4 Expression of TLR2, Fpr2, CD3-γ, TCR-ζ chain, CD137, CB1, CB2, and MBP mRNAs in the brainstem and cerebellum of MOG35-55 immunized mice treated with Veh or PEALut

From: A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis

 

Brainstem

Cerebellum

PID

PID

7

14

21

7

14

21

TLR2/GADPH

Veh

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.4

1.0 ± 0.3

MOG/Veh

0.7 ± 0.2

12.0 ± 2.8°°°

4.6 ± 0.8

0.7 ± 0.0

17.3 ± 7.6°°

16.2 ± 6.6°

MOG/PEALut

1.0 ± 0.3

6.8 ± 1.9*

3.2 ± 0.6

0.8 ± 0.4

2.6 ± 0.7*

9.7 ± 4.8

Fpr2/GADPH

Veh

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.4

1.0 ± 0.2

1.0 ± 0.1

MOG/Veh

1.4 ± 0.5

45.6 ± 11.8°°°

8.0 ± 2.8

1.3 ± 0.3

50.7 ± 26.2°°

32.3 ± 13.0

MOG/PEALut

1.6 ± 0.5

24.6 ± 9.1*

5.1 ± 1.4

1.9 ± 0.2

22.6 ± 11.2

17.3 ± 4.1

CD3γ/GADPH

CTRL

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

MOG/Veh

1.2 ± 0.6

72.7 ± 9.1°°°

44.6 ± 11.4°°°

1.5 ± 0.4

140.4 ± 72.2°°

151.0 ± 40.7°°

MOG/PEALut

1.3 ± 0.3

35.2 ± 14.4**

31.8 ± 8.8

0.9 ± 0.3

31.0 ± 13.8*

105.7 ± 33.9

TCR-ζchain/GADPH

CTRL

1.0 ± 0.3

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.4

1.0 ± 0.1

1.0 ± 0.1

MOG/Veh

0.9 ± 0.2

45.1 ± 8.0°°°

19.3 ± 4.6°°

1.4 ± 0.3

10.6 ± 4.5°°

8.5 ± 1.9°

MOG/PEALut

0.8 ± 0.2

19.2 ± 7.5***

13.1 ± 3.3

1.4 ± 0.2

3.2 ± 1.1*

7.1 ± 2.2

CD137/GADPH

Veh

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

MOG/Veh

1.0 ± 0.0

140.7 ± 47.0°°°

11.9 ± 2.6

1.4 ± 0.0

27.9 ± 13.4°°°

7.3 ± 1.4

MOG/PEALut

1.2 ± 0.0

50.9 ± 20.3**

9.6 ± 2.2

1.8 ± 0.4

5.9 ± 1.2**

6.0 ± 1.4

CB2/GADPH

Veh

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.3

1.0 ± 0.0

1.0 ± 0.3

1.0 ± 0.2

MOG/Veh

1.2 ± 0.1

19.0 ± 5.7°°°

7.4 ± 2.0°°

0.9 ± 0.1

8.1 ± 2.8°°°

7.5 ± 1.9°°

MOG/PEALut

1.5 ± 0.1

6.5 ± 2.5**

6.3 ± 2.3

1.5 ± 0.3

2.9 ± 0.5*

5.7 ± 1.8

CB1/GADPH

Veh

1.0 ± 0.2

1.0 ± 0.3

1.0 ± 0.2

1.0 ± 0.5

1.0 ± 0.2

1.0 ± 0.1

MOG/Veh

0.8 ± 0.2

1.1 ± 0.3

1.2 ± 0.3

1.0 ± 0.2

0.9 ± 0.2

1.1 ± 0.1

MOG/PEALut

0.8 ± 0.1

1.3 ± 0.5

1.1 ± 0.3

1.6 ± 0.4

1.1 ± 0.3

0.9 ± 0.1

MBP/GADPH

CTRL

1.0 ± 0.2

1.0 ± 0.1

1.0 ± 0.1

1.0 ± 0.0

1.0 ± 0.1

1.0 ± 0.1

MOG/Veh

1.1 ± 0.0

0.9 ± 0.0

0.8 ± 0.0

0.8 ± 0.1

0.8 ± 0.2

1.1 ± 0.1

MOG/PEALut

1.1 ± 0.1

1.0 ± 0.1

1.0 ± 01

1.0 ± 0.1

0.8 ± 0.1

0.9 ± 0.0

  1. Mice were treated with Veh, MOG/Veh, or MOG/PEALut for 7, 14, and 21 days. Veh or PEALut treatments started at 11 PID. TLR2, Fpr2, CD3γ, TCR-ζ chain, CD137, CB1, CB2, and MBP mRNA values are reported as mean ± SEM. n = 6 mice for each group. Data are shown as relative expression of Veh-treated values normalized to 1. n = 6 mice for each group. °p < 0.05, °°p < 0.01, and °°°p < 0.001 compared with the Veh-treated group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the MOG/Veh